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A new era in human medicine began in the 1930’s with the discovery of antimi-
crobial agents. Sulfonamides were the first antibiotics introduced into the hospital.
Although penicillin was first discovered in 1929, this drug has only been deployed
for therapy of bacterial diseases in humans since 1940. In the following decades, a
wide variety of antibiotics such as streptomycin, chloramphenicol, tetracycline,
erythromycin and quinolones have been developed. Soon after their introduction in
human medicine, antibiotics were also used in veterinary medicine to treat and to
prevent infectious diseases in animals. Additionally, subtherapeutic doses of antibi-
otics were used as feed additives to improve growth rate in animals. However, infec-
tiology soon became confronted with bacteria that developed antibiotic resistances,
which since the 1980’s led to severe problems in antibiotics therapy (1). Moreover,
since that time, the development of antibiotics consisted solely of modifications and
improvements of existing drugs, but not of the discovery of a new class of antibi-
otics. Important pathogenic bacteria such as Salmonella, Escherichia coli, Campy-
lobacter, Mycobacterium tuberculosis, staphylococci, enterococci and Pseudomonas
species are today resistant to many antibiotics. Bacteria possess several mechanisms
to fight back at antibiotics thereby developing resistances. This results from either
specific DNA mutations that modify targets or from the acquisition of antibiotic
resistance genes that specify for enzymes that can inactivate antibiotics, prevent
their access to their targets or generate their removal out of the cell. Such genes can
be found on transmissible genetic elements like plasmids, transposons or integrons
that can be exchanged between bacteria (2).
In Europe, many antibiotics that have been used as growth promoters have
belonged to the same classes as important antibiotics used in human medicine.
Thereby, antibiotic resistant bacteria from animal origin were selected for and
turned out to show cross resistance against antibiotics currently used in human med-
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icine (3, 4). The use of these antibiotics as feed additives represents a threat to the
effectiveness of antibiotic therapy particularly if antibiotic resistance genes are trans-
mitted to pathogenic bacteria that cause human and animal diseases (5). The mul-
tidrug resistant Salmonella Typhimurium DT104 originally isolated from cattle, has
spread worldwide and represents a significant hazard to humans (6, 7, 8). Isolates of
Salmonella Typhimurium DT104 that are resistant to up to nine different antibiotics
are currently encountered (9). Furthermore, vancomycin resistant enterococci from
animal origin harbouring transferable vanA genes can potentially transfer the van-
comycin resistance gene to multidrug resistant Staphylococcus aureus (10).
To face the increasing amount of antibiotic resistant bacteria and to limit the
potential transfer of antibiotic resistance genes of resistant bacteria from animals to
human pathogens, the Swann Committee of the United Kingdom recommended in
1969 that antibiotics used for therapeutic purposes or generating cross-resistances
to therapeutically used antibiotics should not be used as growth promoters (11). In
response to the Swann Committee, some antibiotics such as penicillin, streptomycin
and tetracyclines have been restricted to therapeutic use only. However, eleven
other antimicrobial substances were still allowed to be used as growth promoters
until their withdrawal in the late 1990’s (see below). The authorized drugs included
avoparcin, bacitracin, flavomycin, spiramycin, tylosin, virginiamycin, carbadox,
olaquindox, monensin, salinomycin and avilamycin.
Regulation of antibiotic use in food-producing animals in the EU and in
Switzerland
In the European Union, the use of antibiotics in feeding stuff and in veterinary
medicine are regulated separately: the decisions for antimicrobial growth promoting
feed additives are made through the European Commission, after consultation with
the Scientific Committee on Animal Nutrition and after hearing the member states.
The regulations of growth promoting antimicrobial feed additives are based on the
1970 Council directive (70/524/EEC) including its amendments (especially
96/51/EC). The individual EU countries regulate the authorization of antibiotics
for animal therapy. This led to the situation whereby certain antibiotics authorized
in some countries are forbidden in others. To obtain an EU wide authorization for
sales, drug companies must get first the approval from The European Agency for
the Evaluation of Medicinal Products (EMEA) (http://www.emea.eu.int) (12) and
then from the European Commission.
In Switzerland, the regulations concerning the use of antibiotics as growth pro-
moters are listed in the Federal Law for Agriculture (LAgr SR 910.1). The Federal Law
on Medicinal Products and Medicinal Devices [Law on Therapeutic Products SR
812.21 (January 1st, 2002)] regulates the use of antibiotics in veterinary medicine.
Antibiotics can only be used under the control of a veterinarian and the animal owners
must register the antibiotic use in a treatment book. The Federal Laws can be found in
French, German or Italian under the link http://www.admin.ch/ch/f/ rs/rs.html.
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Ban of antimicrobial growth promoters in the EU and in Switzerland
In 1986 Sweden, not yet a member of the EU, accomplished pioneering work by
banning antibiotic use in animals for non-therapeutic purposes, whereas the antimi-
crobial feed additives listed above were still in use in the other countries of the EU.
A significant turn-around occurred when glycopeptide resistant enterococci from
animal origin sounded the alarm (13, 14). Enterococcus strains isolated from pigs and
chickens were found to harbour the vancomycin resistance gene vanA on a transfer-
able element (15, 16). Avoparcin, a glycopeptide antibiotic like vancomycin, had
been used as a feed additive for more than 20 years, while at the same time van-
comycin was reserved in human medicine as the last weapon to treat infections
caused by methicillin resistant Staphylococcus aureus (MRSA). The authorization
for avoparcin was then withdrawn in Denmark in May 1995, in Germany in January
1996 and in December 1996 in all other EU countries as a preventive measure to
avoid the spread of vancomycin resistance to important pathogens (Commission
directive 97/6/EC amending Directive 70/524/EEC). It was also decided in January
1998, not to renew the authorization of ardacin, another glycopeptide antibiotic
used in feeding stuff (Commission Directive 97/72/EC). Similarly, the Council of
Agriculture Ministers decided in December 1998 to withdraw the authorization to
use the macrolide antibiotics tylosin and spiramycin as well as the streptogramin
antibiotics virginiamycin and bacitracin as growth promoting feed additives begin-
ning July 1st 1999 (Council regulation (EC) No. 2788/98). Macrolides used as
growth-promoting feed additives were considered to contribute to the selection of
resistant bacteria such as enterococci with the possibility that macrolide resistant
Enterococcus strains and erm-genes (gene conferring cross-resistance to macrolides,
lincosamides and streptogramins) could become a threat to human medicine.
Macrolides are currently important antibiotics in human medicine, used to treat
among others, important respiratory tract infections. The streptogramin antibiotic
virginiamycin is suspected to select for the streptrogramin resistance gene (satA)
that has been shown to be widespread in Enterococcus species from pig and poultry
origin (17, 18). Two streptogramin antibiotics, namely pristinamycin and the com-
bination dalfopristin/quinupristin are clinically important in human medicine as a
last-resort treatment of infections with vancomycin resistant enterococci and
staphylococci. In view of their possible adverse effect on human health (genotoxic-
ity), the authorizations for the growth promoters olaquindox and carbadox were
withdrawn from the directive 70/524/EEC in December 1998 entering into force
August 31st 1999 (Commission Regulation (EC) No 2788/98). By the end of 1999,
four antibiotics were still authorized: avilamycin, flavophospholipol (bam-
bermycin), monensin and salinomycin. In March 2002, the European Commission
presented new proposals to prohibit any antibiotic for use as growth-promoting
feed additives. Under these proposals, the four remaining authorized antibiotics
would have to be phased out by January 1st 2006. The EU Council directives and
amendments are available on the EurLex website (http://europa.eu.int/eur-lex).
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In Switzerland, the use of all growth-promoting antibiotics was banned by Jan-
uary 1st 1999. The regulation is to be found in Article 160, Paragraph 8 of the Fed-
eral Law for Agriculture (LAgr SR 910.1) revised in April 1998 and entered into
force January 1st 1999.
Amount of antibiotics used for animals in Europe and Switzerland
A study conducted by the European Federation of Animal Health (FEDESA)
(http://www.fedesa.be) estimated that in Europe, human consumption represented
65% of the total volume of antibiotics prescribed in 1999 (8528 tons) while animals
consumed 35% (4688 tons). Due to the ban, the consumption of antibiotics used as
growth promoters dropped by 50% from 1997 (1599 t) to 1999 (786 t). However,
the amount of therapeutic antibiotics used in the EU for animals increased 11% in
the same period: 3494 t in 1997 and 3902 t in 1999. In Switzerland, the amount of
antibiotics used in animal husbandry is based on the volume of antibiotics imported.
The import of antibiotics used as growth-promoting feed additives decreased by
99.8% between 1995 and 2001. The import of antibiotics used in therapeutic feed
was reduced by one half from the same period. However, the amount of antibiotics
used for medical treatment of single animals increased by 23% from 1995 to 2001.
In general, the import of antibiotics for animal use has dropped by 50% in Switzer-
land over the past six years, going from 80.1 t in 1995 to 34.1 t in 2001 (data obtained
from the Federal Office for Agriculture, Berne, Switzerland). The amount of antibi-
otics imported into the country gives only an indication of the quantity of antibi-
otics used in animals, as no detailed data are available on the effective volume of
antibiotics consumed by animals. To determine the effective amount of antibiotics
consumed by pigs, the quantity of active ingredients prescribed yearly by veterinar-
ians for medicated feed was reported for one Swiss canton from 1996 to 2001. This
study conducted by Swissmedic (http://www.swissmedic.ch) showed that the
amount of antimicrobials effectively consumed by pigs decreased from 1200 kg of
active ingredients in 1996 to 935 kg in 2001 (19).
Effect of the ban of antimicrobial growth promoters on the resistances of
bacteria
The resistance profile of Enterococcus species isolated from faecal samples of
pigs receiving the macrolide antibiotic tylosin as an antimicrobial growth promoter
before the ban was compared with that of Enterococcus species isolated in the same
farms six month after the ban. A clear decrease in resistance to the macrolides eryth-
romycin and spiramycin and to the lincosamide clindamycin was observed (20). In
enterococci, the resistance to macrolides, lincosamides and streptogramins are most
likely due to the presence of one single gene erm(B), which seems to be vanishing in
enterococci of porcine origin since the ban of antimicrobial growth promoters in
Switzerland.
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Use of antibiotics as therapeutics in food-producing animals
Antibiotics authorized for therapy in food-producing animals in the EU and in
Switzerland are the same or are structurally related to those used in human medi-
cine. Animals are either treated individually by injection or by oral administration
of antibiotics. Entire herds are often treated with antibiotics mixed in with the feed
(medicated feed) to prevent or cure bacterial diseases. The oral administration of
antibiotics through medicated feed for herd treatment constitutes a stronger selec-
tive pressure on the surrounding microflora than administration by injection and
thus selects for antibiotic resistant bacteria. In Switzerland, chlortetracycline, sul-
fadimidine and the combination sulfonamide/trimethoprim are the most prescribed
antibiotics for medicated feed in pig production (19). Escherichia coli isolated from
pigs suffering from diarrhea and oedema diseases were screened for antibiotic resist-
ance (21). Resistance to sulfonamide (81%), tetracycline (54%), streptomycin
(37%), spectinomycin and the combination sulfonamide/trimethoprim (20%) were
the most frequent, indicating that a correlation exists between the antibiotics com-
monly used in pig breeding and the frequency of resistance found in E. coli. Resis-
tance data have been compared with those from Sweden (22). Sweden has not used
any antibiotics as growth promoters since 1986 and uses mainly tetracycline, the
combination sulfonamide/trimethoprim and streptomycin as therapeutics in pig
production. Additionally, it has a vaccination program to prevent neonatal piglet
diarrhea. In Sweden like in Switzerland, the resistance levels are correlated with the
type of antibiotics used. Indeed in Sweden, pathogenic E. coli from pigs showed
mainly resistance to tetracycline (35%), streptomycin (27%) and the combination
sulfonamide/trimethoprim (20%). However, the frequency of antibiotic resistant
bacteria is significantly higher in Switzerland than in Sweden.
Pigs in Switzerland as a reservoir of new antibiotic resistance genes
In Switzerland, the sulfonamide resistance of pathogenic E. coli from pigs was
shown in 70% of the cases to be due to sul1 or sul2 genes (21). The mechanism of
sulfonamide resistance for the remaining 30% of the isolates could be explained by
the presence of the new sulfonamide resistance gene sul3 (23). The sul3 gene, flanked
by two mobile insertion sequences and located on a conjugative plasmid has a
strong potential for dissemination within the bacterial population.
Monitoring of antibiotic resistance and surveillance of antibiotic use
The European Commission has responded to the emerging problem of antibi-
otics resistance by funding the European Antimicrobial Resistance Surveillance Sys-
tem (EARSS; http://www.earss.rivm.nl) that collects comparable and validated
antimicrobial susceptibility data of clinical isolates from more than 600 laboratories
in 27 countries. The data are published in their annual report (EARSS Annual
Report 2001). Monitoring systems and surveillance of antimicrobial resistance in
bacteria from food animals have been in place for some years and are published by
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the Scandinavian countries Denmark (DANMAP 2001 (24)), Sweden (SVARM
2001 (22)) and Norway (NORM VET 2000 (25)). In Switzerland, a systematic sur-
veillance program of resistance has yet to be established. Additionally, the surveil-
lance of antibiotic resistance should definitely be correlated with a surveillance of
antimicrobial usage to develop a prescription system (appropriate use and amount
of antibiotics) to avoid the selection of new or existing antibiotic resistance and to
optimize the therapy.
In Europe, an effort has been made to reduce the use of antimicrobials in food-
producing animals. Current data show that antibiotic resistance in bacteria from
animal origin has significantly decreased since the ban of antibiotics as growth pro-
moters. In Sweden in particular, where the use of antimicrobial feed additives was
abolished in 1986 and where good surveillance programs have been applied, we
observe a very low level of antibiotic resistant pathogens isolated from animals.
A prudent and appropriate use of antibiotics in food-producing animals (e.g.
single animal treatment) has to be correlated with good manufacturing practices,
good hygiene and vaccination programs. This will keep the level of resistances in
bacteria low and avoid the emergence of incurable bacterial diseases.
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Summary
The intensive and inappropriate use of antibiotics in both medicine and agricul-
ture has selected for antibiotic resistant bacteria that cause severe problems in
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antibiotic therapy. In animal husbandry, antibiotics are used for therapeutic and
preventive treatments of infectious diseases and as growth promoters. In Europe,
many antibiotics used as growth promoters were of the same classes as important
antibiotics used in human medicine. The European Union withdrew the authoriza-
tion for the use of the major antimicrobial growth promoters between 1996 and
1999. In 1999 Switzerland decided to ban the use of all antimicrobials as growth-
promoting feed additives. The regulations concerning antibiotic use in animal hus-
bandry and the chronological reasons for the ban of antimicrobial growth promot-
ers are described. This ban led to a decrease of the antibiotic volume deployed in
agriculture. This measure helps to reduce the amount of antibiotic resistant bacteria
in food-producing animals. However, the use of medicated feed is still a common
practice to prevent and to remedy bacterial infections and thus still leads to resistant
pathogens. Surveillance programs, single animal treatment, good manufacturing
practices and vaccinations are additional measures to be taken to keep the level of
resistances in bacteria low.
Zusammenfassung
Durch den intensiven und nicht gezielten Einsatz von Antibiotika in der Medi-
zin und in der Landwirtschaft haben pathogene Keime Resistenzen gegen eine Viel-
zahl von Antibiotika entwickelt. Das Auftreten multiresistenter Krankheitserreger
führt heute zu grossen Schwierigkeiten bei Antibiotika-Behandlungen. Antibiotika
werden bei Tieren zu prophylaktischen und therapeutischen Zwecken sowie als
Wachstumsförderer eingesetzt. Viele, als Wachstumsförderer eingesetzte Antibio-
tika, waren mit Antibiotika eng verwandt, welche in der Humanmedizin eingesetzt
werden. Die Europäische Union hat zwischen 1996 und 1999 die Bewilligungen für
gewisse antimikrobielle Wirkstoffe als Leistungsförderer zurückgezogen. In der
Schweiz sind alle antimikrobiellen Leistungsförderer seit 1999 verboten. Seitdem
wurde die in der Landwirtschaft eingesetzte Menge von Antibiotika reduziert.
Dadurch wird der Selektivdruck reduziert, und die Anzahl resistenter Bakterien
nimmt ab. Die Anwendung von Antibiotika im Futtermittel ist jedoch weiterhin
eine gewöhnliche Praxis zur Verhinderung und Behandlung von Infektionskrank-
heiten. Dies führt immer noch zur Erzeugung von Antibiotika-resistenten Krank-
heitserreger. Aus diesem Grund sind Überwachungsprogramme, die Praxis der
Einzeltier-Behandlung, gute Merkblätter der Antibiotikahersteller sowie eine rigo-
rose Hygiene notwendig um eine weitere Verminderung von Antibiotika-resisten-
ten Keimen zu erreichen.
Résumé
L’utilisation intensive et inappropriée d’antibiotiques en médecine et dans l’agri-
culture a eu pour effet de sélectionner des bactéries de plus en plus résistantes aux
antibiotiques. Certaines infections bactériennes sont aujourd’hui devenues difficiles à
traiter par les antibiotiques. Chez les animaux d’élevage, les antibiotiques sont utilisés
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pour traiter et prévenir les maladies infectieuses, mais aussi comme stimulateur de
croissance. En Europe, de nombreux antibiotiques utilisés comme stimulateur de
croissance étaient de la même famille que ceux utilisés en médecine humaine. Ainsi
entre 1996 et 1999, l’Union Européenne a retiré les autorisations pour l’utilisation de
la plupart des antibiotiques comme stimulateur de croissance. En Suisse, toute sub-
stance antibiotique a été interdite comme stimulateur de croissance dès 1999. Depuis
ces interdictions, le volume d’antibiotiques utilisés en agriculture a considérablement
diminué. En l’absence de pressions sélectives, le nombre de bactéries résistantes aux
antibiotiques diminue aussi. Pourtant, l’utilisation d’antibiotiques directement
mélangés au fourrage reste une pratique prophylactique et thérapeutique courante
contre les infections bactériennes. Cette pratique présente également le risque d’in-
duire des résistances chez des bactéries pathogènes. Des programmes de surveillance
des résistances, un traitement individuel des animaux, de bonnes pratiques d’élevage
et d’hygiène pourront permettre de limiter le nombre de résistances chez les bactéries.
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